Haloperidol enhances latent inhibition in visual tasks in healthy people

Psychopharmacology

Volumn 133, Issue 3, 1997, Pages 262-268

  Williams, Jonathan H ^a,c   Wellman, Nigel A ^a   Geaney, David P ^a   Feldon, Joram ^b   Cowen, Philip J ^a   Rawlins, J N P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Inst Vet Pharmacol and Toxicol   (Switzerland)

^c Princess Marina Hospital   (United Kingdom)

Author keywords

Antipsychotic drugs; Haloperidol; Healthy volunteers; Latent inhibition; Schizophrenia; Schizotypy

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LATENT INHIBITION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; SCHIZOPHRENIA; VISION;

EID: 0030810623     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050400     Document Type: Article

References (56)

1. Angrist B, Rotrosen J, Gershon S (1980) Differential effects of amphetamine and neuroleptics vs. positive symptoms in schizophrenia. Psychopharmacology 72:17-19
2. Allan LM, Williams JH, Wellman NA, Tonin J, Taylor E, Rawlins JNP (1995) Effects of tobacco smoking, schizotypy and number of pre-exposures on latent inhibition in healthy subjects. Person Indiv Diff 19:893-902
3. Anscombe R (1987) The disorder of consciousness in schizophrenia. Schizophr Bull 13:241-260
4. Baruch I, Hemsley DR, Gray JA (1988a) Differential performance of acute and chronic schizophrenics on a latent inhibition task. J Nerv Ment Dis 176:598-606
5. Baruch I, Hemsley DR, Gray JA (1988b) Latent inhibition and "psychotic-proneness" in normal subjects. Person Indiv Diff 9: 777-784
6. Bell DS (1963) Comparison of amphetamine psychosis and schizophrenia. Br J Psychiatry 111:701-707
7. Bleuler E (1913) Dementia praecox or the group of schizophrenias. Translated into English, 1987. In: Cutting J, Shepherd M (eds) The clinical routes of the schizophrenia concept. Cambridge University Press, Cambridge
8. Bruhwyler J, Chleide E, Mercier M (1990) Clozpine an atypical neuroleptic. Neurosci Biobehav Rev 14:357-363
9. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC (1994) Putatively pscychosis-prone subjects 10 years later. J Abnorm Psychol 103:171-183
10. Christison GW, Atwater GE, Dunn LA, Kilts CD (1988) Haloperidol enhancement of latent inhibition: relation to therapeutic action? Biol Psychiatry 23:746-749
11. Claridge GS, Broks P (1985) Schizotypy and hemisphere function. I. Theoretical considerations and measurement of schizotypy. Person Indiv Diff 5:633-648
12. Collett D (1994) Modelling survival data in medical research. Chapman and Hall, London
13. Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London
14. Crider A, Solomon P, McMahon M (1982) Disruption of selective attention in the rat following chronic d-amphetamine administration: relationship to schizophrenic attention disorder. Biol Psychiatry 17:351-361
15. De la Casa LG, Ruiz G, Lubow RE (1993) Latent inhibition and recall/recognition of irrelevant stimuli as a function of preexposure duration in high and low psychotic-prone normal subjects. Br J Psychol 84:119-132
16. Dunn LA, Atwater G, Kilts CD (1993) Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioural model of clinical drug action. Psychopharmacology 112:315-323
17. Ellenbroek BA, Cools AR (1990) Animal models with construct validity for schizophrenia. Behav Pharmacol 1:469-490
18. Eysenck HJ, Eysenck SBG (1975) Manual of the Eysenck personality questionnaire. Hodder and Stoughton, London
19. Eysenck HJ, Eysenck SBG (1976) Psychoticism as a dimension of personality. Hodder and Stoughton, London
20. Feldon J, Weiner I (1991a) An animal model of attentional deficit. In: Boulton AA et al. (eds) Neuromethods vol 18, animal models in psychiatry. Humana Press, Clifton, N.J.
21. Feldon J, Weiner I (1991b) The latent inhibition model of schizophrenic attention disorder: haloperidol and sulpiride increase rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29: 635-646
22. Feldon J, Weiner I (1992) From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J Psychiatr Res 26:345-366
23. Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological effects. Drugs 40:722-747
24. Goff DC, Henderson DC, Amico E (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149:1189-1194
25. Gray JA, Feldon J, Rawlins JNP, Hemley DR, Smith AD (1991) The neuropsychology of schizophrenia. Behav Brain Sci 14:1-84
26. Gray NS, Hemsley DR, Gray JA (1992a) Abolition of latent inhibition in acute but not chronic, schizophrenics. Neurol Psychiat Brain Res 1:83-89
27. Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA (1992b) Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology 107:425-430
28. 2 binding using SPET. Schizophr Res 17:95-107
29. Joseph MH, Peters SL, Gray JA (1993) Nicotine blocks latent inhibition in rats: evidence for a critical role of increased functional activity of dopamine in the mesolimbic system at conditioning rather than pre-exposure. Psychopharmacology 110: 187-192
30. Killcross AS, Robbins TW (1993) Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology 110:479-489
31. Killcross AS, Dickinson A, Robbins TW (1994) Effects of the neuroleptic α-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms: evidence for dopamine-reinforcer interactions. Psychopharmacology 115:196-205
32. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ (1992) Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160:179-186
33. Lipp OV, Vaitl D (1992) Latent inhibition in human Pavlovian conditioning: effect of additional stimulation after preexposure and relation to schizotypal traits. Person Indiv Diff 13: 1003-1012
34. Lipp OV, Siddle DAT, Arnold SL (1994) Psychosis proneness in a non-clinical sample I. Multi-experimental study of "attentional malfunctioning". Person Indiv Diff 17:405-424
35. Lohr JB, Flynn K (1992) Smoking and schizophrenia. Schizophr Res 8:93-102
36. Lubow RE (1973) Latent inhibition. Psychol Bull 79:398-407
37. Lubow RE (1989) Latent inhibition and conditioned attention theory. Cambridge University Press, Cambridge
38. Lubow RE, Moore AU (1959) Latent inhibition: the effect of non-reinforced pre-exposure to the conditional stimulus. J Comp Physiol Psychol 52:415-419
39. Lubow RE, Weiner I, Schlossberg A, Baruch I (1987) Latent inhibition and schizophrenia Bull Psychon Soc 25:464-467
40. Lubow RE, Ingeberg-Sachs Y, Zalstein-Orda N, Gewirtz JC (1992) Latent inhibition in low and high "psychotic-prone" normal subjects. Person Indiv Diff 13:563-562
41. MacDonald N (1960) The other side: living with schizophrenia. Can Med Assoc J 82:218-221
42. Moran PM, Fischer TR, Hitchcock JM, Moser PC (1996) Effects of clozapine on latent inhibition in the rat. Behav Pharmacol 7:42-48
43. Pakkenberg B (1990) Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 47:1023-1028
44. Roberts GW (1991) Schizophrenia: a neuropathological perspective. Br J Psychiatry 158:8-17
45. Solomon PR, Staton DM (1982) Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore an irrelevant stimulus. Biol Psychiatry 17:743-756
46. SPSS (1993) Advanced statistics. SPSS Inc., Chicago
47. Swerdlow NR, Braff DL, Hartston H, Perry W, Geyer M (1996) Latent inhibition in schizophrenia. Schizophr Res 20:91-103
48. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994) Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114:657-664
49. Weiner I, Feldon J (1987) Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology 83:248-253
50. Weiner I, Feldon J, Katz Y (1987) Facilitation of the expression but not of the acquisition of latent inhibition by haloperidol in rats. Pharmacol Biochem Behav 26:241-246
51. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996) The latent inhibition model of schizophrenia : further validation using the atypical neuroleptic, clozapine. Biol Psychiatry 40: 834-843
52. Weiner I, Gal G, Rawlins JNP, Feldon J (1997) Differential involvement of the shell and core subterritories of the nucleus accumbens in latent inhibition and amphetamine-induced activity. Behav Brain Res (in press)
53. Williams JH, Wellman NA, Geaney DP, Rawlins JNP, Feldon J, Cowen PJ (1996a) Anti-psychotic drug effects in a model of schizophrenic attentional disorder: a randomised controlled trial of the effects of haloperidol on latent inhibition in healthy people. Biol Psychiatry 40:1135-1143
54. Williams JH, Wellman NA, Geaney DP, Cowen PJ, Feldon J, Rawlins JNP (1996b) Latent inhibition is not reduced in drug-free patients with schizophrenia. Paper presented at the VIIIth Biennial European Workshop on Schizophrenia, Crans Montana, Switzerland, March 1996. Schizophr Res 18:202 (Abstract)
55. Williams JH, Wellman NA, Geaney DP, Rawlins JNP, Feldon J, Cowen PJ (1997) Intravenous administration of haloperidol to healthy volunteers: lack of subjective effects but clear objective effects. J Psychopharmacol (in press)
56. Yee BK, Feldon J, Rawlins JNP (1995) Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region but this lesion effect can be prevented by systemic haloperidol treatment. Behav Neurosci 109:227-240